

REVIEW
ARTICLEHepatitis C Infection in the General Population of Iran:
A Systematic ReviewSeyed Moayed Alavian ^{1*}, Masoud Ahmadzad-Asl ², Kamran Bagheri Lankarani ³,
Mohammad Ali Shahbabaie ², Amir Bahrami Ahmadi ², Ali Kabir ²¹ Baqiyatallah Research Center for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, Tehran, Iran² Department of Clinical Researches, Nikan Health Researchers Institute, Tehran, Iran³ Department of Gastroenterology and Hepatology, Shiraz University of Medical Sciences, Shiraz, Iran

Background and Aims: There is no overall estimate of hepatitis C infection (HCV) in Iran. We reviewed all of the published and unpublished evidence related to HCV infection in Iran in order to accurately estimate the prevalence of HCV infection in the Iranian general population to inform future health system programs.

Methods: In this systematic review, all papers, medical congresses, HCV-related reports, projects of Iranian research centers and medical universities, reports from the Deputy for Health Affairs (published or unpublished), and online theses about HCV in Iran were included. We selected descriptive and analytic cross-sectional studies and surveys related to the prevalence of HCV infection in the Iranian general population between 2001 and 2008 that have sufficiently declared objectives, proper sampling methods with identical and valid measurement instruments for all study subjects and proper analysis methods regarding sampling design and demographic adjustments. We used a survey data analysis method to estimate the national prevalence rate.

Results: From the 6,431 studies we investigated, eight eligible studies reported a prevalence of HCV infection in the general population. They were from six (out of 30) provinces, in which about 43 percent of the country's population lives. We calculated that the HCV infection prevalence rate in Iran is 0.16% (95% confidence interval [CI]: 0% -0.59%).

Conclusions: In comparison with similar studies, the prevalence of HCV infection in Iran is low. This might be a result of having prevention programs for high-risk groups and strict blood screening programs.

Keywords: Hepatitis C, Iran, Prevalence, Epidemiology

Introduction

Hepatitis C virus (HCV) infection is a major global public health problem in both developed and developing countries ⁽¹⁾. HCV infection is transmitted mainly by exposure to infected blood or blood products, infected medical equipment despite strict hygienic control, intravenous drug abuse, hemodialysis, and organ transplantation ^(2, 3). There are some studies on the prevalence of HCV infection in the Iranian population that have focused specifically on healthy blood donors. The first paper in this line of literature was published in 1994 and found the prevalence of HCV infection to be 0.3% in blood donors ⁽²⁾. In

previous studies, the prevalence of HCV infection

*** Correspondence:**

Seyed Moayed Alavian, M.D.

Founder of Iran Hepatitis Network & Tehran Hepatitis Center,
Professor of Internal Medicine, Gastroenterology and
Hepatology, Baqiyatallah Research Center for Gastroenterology
and Liver Diseases, Grand floor of Baqiyatallah Hospital,
Mollasadra Ave., Vanak Sq., P.O. Box: 14155-3651, Tehran, Iran.

Tel/Fax: +98 21 8126 2072

E-mail: Alavian@thc.ir

Received: 30 May 2009

Revised: 9 Aug 2009

Accepted: 11 Aug 2009

Hepat Mon 2009; 9 (3): 211-223

was reported to be between 0.08% and 1.3% of the Iranian general population and blood donors in different provinces⁽³⁻⁶⁾. According to the Iranian national census of 2006, the national population of Iran was 70,495,782 persons⁽⁷⁾.

In 2003, it was estimated that HCV infection affected nearly 170 million people worldwide⁽⁸⁾. The rate of occurrence in some regions or among high-risk groups such as injecting drug users, Hemophilia and thalassemia patients, and patients undergoing hemodialysis may be as high as 30%-90%⁽⁹⁾. Epidemiologic evidence of HCV is one of the main evidences for strategic prevention of chronic liver diseases.

HCV infection is detected by some laboratory methods such as enzyme-linked immunosorbant assay (ELISA), recombinant immunoblot assay (RIBA), and polymerase chain reaction (PCR). Generally ELISA is used as a screening tool, RIBA is used as a complementary test, and PCR is used as a confirmatory test. HCV antibody detection with ELISA has a low specificity and positive predictive value for low-risk groups such as blood donors and the general population⁽¹⁰⁾. In one study in China, with a single ELISA test as the HCV detection method, the false negative rate was nearly 17% in HCV infectors. After adding PCR to ELISA for HCV detection, false positive results decreased⁽¹¹⁾. Assessment of predicted rate for infected patients, diagnosis and treatment of high-risk groups in the community could be achieved by most effective and preventive programs in reducing the rate of HCV infection. This, or any other effective program, needs more accurate estimates of the prevalence of HCV infection in the country.

In Iran, we do not have an overall estimate of HCV infection, and the studies that have been done on HCV prevalence are restricted to specific geographic locations or provinces.

In the present systematic review, we reviewed the papers on HCV infection in Iran in order to accurately estimate the HCV infection prevalence rate in Iran in order to help promote HCV prevention programs.

Materials and Methods

We estimated the prevalence of HCV in the Iranian general population with a comprehensive systematic review of the literature and evidence followed by integrating the data and an analysis of the findings.

Our study population was the Iranian general population, and the outcome of interest was the presence of positive HCV antibody in blood samples of the study population, based on any of the blood tests such as ELISA or RIBA/PCR even if other laboratory tests are not identified clearly, from April 2001 to March 2008.

For electronic and hand searching we used "Hepatitis C", "HCV," and "Iran" (or the names of its provinces) as key words for titles and/or abstracts in a MeSH word search. We also used different text words (specifically in searching national databases) to increase the sensitivity of the search.

We searched 15 electronic databases of the health and biological sciences including Google Scholar, ISI, Scopus, EMBASE, Medline, WHO, CINAHL, DOAJ, CABI, High-Wire Press, EBM Review, EMR medex, Cochrane, NLM Gateway, and DARE. Furthermore, four Iranian databases on the medical and life sciences literature were used including Iran Medex, SID, Magiran and IranDoc. Hence, the study covered all registered and certified life sciences and medical journals at the national level.

In a gray literature search, we found 243 national, regional, and international Iranian medical science congresses in the study time period. We selected and hand searched 67 out of 243 relevant congress abstract books by two independent reviewers. We also searched the research projects of 29 out of 40 Iranian universities of medical sciences from their websites. We contacted the Center for Disease Control (CDC) of the Iranian Ministry of Health and the Iranian Blood Transfusion Organization (IBTO) for searching national reports from the study time period. Medical students' theses were also evaluated by two independent reviewers from the Iranian center for scientific documents and records (IranDoc). Finally, we consulted eight expert HCV researchers in Iran and searched their personal archives for additional citations. Forward and backward citations of searched items were also performed.

Two independent reviewers reviewed all citations thoroughly and checked for eligibility criteria to include the studies in the analysis. The inclusion criteria were all cross-sectional studies that specified temporal and geographic characteristics of the study; sufficiently declared objectives; and that used a valid

sampling method that allowed for a generalization of the findings to the target population, valid measurement instruments for all study subjects, and appropriate analytic methods for the given sampling design and demographic characteristics. We revised the criteria developed by Sharifi for this purpose (12).

After evaluating studies on these criteria, we extracted the findings of the included studies to Excel spreadsheets. The extracted data were year of the study, first author, province and district of the study, sample population, sampling method, sample size, HCV Antibody detection method, HCV Antibody kit name, mean age and standard error (SE) of subjects, percentage of male subjects, and HCV point prevalence in study subjects and/or in males/females and its SE. If there were other parameters reported other than SE, such as standard deviation, confidence interval, and/or P-value, the proper modifications were performed to calculate SE.

We analyzed the extracted data to estimate the point prevalence of HCV infection and its 95% confidence interval (CI) and used a Cochrane Q-test with a significance level of < 0.1 for checking the statistical heterogeneity of the results. We used a meta-analysis method with the "meta" command using fix/random model based on the results of the

heterogeneity test. It seems that the meta-analysis method would not have been a suitable method to achieve the objectives of this systematic review because the weighting system of this method only considers sample size and not the size of the provincial population. We used a survey data analysis method to calculate the estimate of the nationwide prevalence rate considering the weight of each province as the ratio of the provincial population to the sample size(s), where the population of each province was retrieved from the Iranian national census at 2006 (7).

In provinces with more than one prevalence study (Tehran and Sistan-va-Baluchestan), the provincial prevalence was calculated by a meta-analysis of the studies, and the total sample size was determined by adding all study sample sizes. The analysis was performed with STATA 9.1 software (STATA Corp. LP). The results were shown in geographic maps using Arc View 3.2a software (ESRI Inc. NY).

Results

After review of studies, we found 190 related studies about HCV prevalence in Iran in literature review (13-192) from 264 studies that were found in electronic databases (Fig. 1). We found no additional unpublished findings on the HCV infection rate in

Figure 1. \$ " !&!" " \$ % ! !

the general population from Iranian medical congresses and reports.

After excluding duplicate and overlapping reports to avoid double counting, we finally selected eleven studies with subjects in the general population. Out of these, two studies were on the Sistan-va-Baluchestan province (98, 113), and three studies were on the Tehran (49, 96, 185) province. From East Azarbaijan (81), Kermanshah (93), Chaharmahal-va-Bakhtiari (30), Khuzestan (35), Guilan (3), and Golestan (25), one study from each province was included in our analysis.

The prevalence rate varied from 0% in the Khuzestan and Tehran provinces (35, 49) to 1.3% in the Guilan province (3). Reported percentages were heterogeneous and statistically significant (Test for heterogeneity: $Q = 1607.73$, $df = 10$, $P < 0.001$) (Fig. 2).

The overall estimate of the HCV prevalence rate in Iran according to data from eleven studies from eight provinces with an ELISA detection test (For HCV-antibody) was 4.45% (95%CI: 1.29%-7.61%). In three studies from Chaharmahal-va-Bakhtiari, East Azarbaijan, and Tehran (96), confirmatory tests were not used; therefore, the studies were excluded from the final analysis. Prevalence of HCV in Iran with Survey Data analysis according to the information from eight studies from

six provinces with RIBA/PCR for HCV infection was %0.16 (95%CI: 0%-0.59%) (Fig. 3).

Discussion

The present study was designed to estimate the HCV infection prevalence rate in the Iranian general population according to available data from literature collected from different provinces by Iranian medical researchers. The prevalence of HCV in Iran with RIBA/PCR for HCV infection was 0.16%.

In our study, the prevalence of HCV infection was evaluated in only eight provinces. These provinces were among the most populous ones in Iran. The total population of these provinces was 30,468,756, making up 43.2% of the country's population. Despite the lack of data for the country as a whole, it seems that the overall estimate in these provinces represents a suitable estimate of the HCV prevalence for the whole country.

The highest HCV infection rate in Iranian general population was reported from one study on the residents of a Guilan nursing home (3). This rate might be due to the lower level of health in this sample. In two studies from Khuzestan (35) and Tehran (49), the HCV infection rate was reported to zero. These low rates could have been due to the study design or the type of sampling method and a small study population. HCV infection rates in provinces that border countries around Iran were significantly higher than the rates in the central regions of our country (Table 1). Some factors such

Figure 2. ! " !"# ! # " \$




Figure 3. HCV prevalence in Iran, 2001-2008

Table 1. HCV prevalence in Iran, 2001-2008

Region	Study	Province	Country	Method	n	Prevalence (%)	Study Population
North	Ghanicie (2007)	Guilan	Azarbaijan (8.7%)	PCR	383	1.3	3
	Ghadir M (2006)	Golestan		RIBA	2123	1	25
West	Sayad B (2008)	Kermanshah	Turkey (2.4%)	PCR	1721	0.87	93
Southeast	Salehi M (2001)	Sistan va Baluchestan	Pakistan (3%)	WB*	919	0.1	98
	Moradi M (2007)	Sistan va Baluchestan		ELISA	365	0.8	113
Center	Vahdani P (2006)	Tehran	None	RIBA	102	0 £	49
	Chamani L (2007)	Tehran		ND	1249	0.16	190
Southwest	Motlagh (2001)	Kuzestan	Kuwait (0.8)	RIBA	80	0 §	35

*: western blot

£: street children

§: pregnant women

as more contact with infected patients and a higher prevalence of HCV in our neighbors may explain the probable cause of the different prevalence of these provinces.

The HCV infection rate in Iranian general population is lower in comparison with other countries in our region (Eastern Mediterranean Region) and even many other countries like China, Europe, and the USA (193-202) (Table 2).

One of the causes of the notable difference in the HCV prevalence rate might be due to the handling of HCV prevention programs by some countries (203, 204). Preventive strategies in countries are based on health policy. Iranian prevention strategy for controlling the hepatitis C infection rate by harm reduction started 10 years ago. This strategy was accepted by the high-level officials of the government. More attention to high-risk groups to detect infected patients and screen and treat them was the fundamental basis of any program that was created with this strategy (205).

HCV prevention programs must be designed to control the risk factors that contribute to the transmission of HCV infection. Blood transfusion is one of the transmission routes of HCV infection. In developed countries, the residual risk for HCV infection through blood transfusion is lower and the current risk estimates per million donations are approximately 0.52 in the USA (206), 0.7 in Canada (207), and 0.1–2.33 in different European countries (208-210). In some developed countries, due to defects

in the collection of samples from non-remunerated blood donors, lack of trained professionals, and a poor supply of instruments and laboratory equipment for suitable blood transfusion, HCV transmission occurs more than in developing countries (211). In some studies, blood donors were selected as the general population. These samples are not actually representative of the general population and may have caused an underestimate of HCV infection in these studies (195). The prevalence rate of HCV in donor populations in some developing countries ranges between 1% and 7% (212-215). A high prevalence of 17% was reported in Egypt (216).

In Iran, we started a blood donor screening program in all Iranian blood transfusion centers in 1996. Some studies have shown that the HCV infection rate was significantly lower than before blood screening (29). The screening process and the elimination of high-risk donors are among the main causes of improvement in blood transfusion services in Iran (154, 192). The strict program of HCV infection screening prior to transfusion is one possible explanation for lower the prevalence of HCV infection rate in our country in comparison with other developing countries (217). Some studies have reported that HCV infection has specific epidemiological characteristics in hemodialysis patients (218-221), thalassemia patients (217), hemophilic patients (88, 222), and intravenous drug abusers (IDUS) (82). These patients are considered at-risk populations and are the primary source of

Table 2. " " ! \$! " " "#

	!			
Syed Asad Ali (2009)	Pakistan/EMRO	ND	3% (blood and non blood donors)	196
Sandesh K (2006)	India/EMRO	ND	0.33% (Blood donors)	197
Ameen. R (2005)	Kuwait/EMRO	ELISA	0.8% (Blood donors)	194
Daw. MA (2002)	Libya/EMRO	ELISA	1.6% (general population)	195
Erden S (2003)	Turkey/EMRO	-	2.4% (hospital based)	198
Lehman EM (2009)	Egypt/EMRO	-	13.9% (healthy populations)	199
Xia X (2008)	China/Asia	-	2.2% (general population)	200
Stvilia K (2006)	Georgia/Europe	RIBA	6.7% (general population)	201
Armstrong GL (2006)	USA/America	-	1.8% (Nationally representative household survey)	202
Galetski (1999)	Azarbaijan (Europe)	ND	8.7%	203

EMRO: Eastern Mediterranean Regional Office; ND: non determined; ELISA: enzyme-linked immunosorbent assay; RIBA: recombinant immunoblot assay.

56E6C>:2E:@? @7 A2E9@=@8:42= 7:?:78D C682C5:78 D92-5CF8 255:4E:@? :?>2E6D :? '2D9E C2?1 4!.\$
DJDE6> :? A2E:6?ED H:E9 49C@?:4 96A2E:E:D 2?5 4:CC9@D:D
25>:EE65 E@ '2D@F= 6 <C2> 9@DA:E2= 36EH66? E@ =2G:2? (" 27266 .6<E2A2C2DE !/ (0%C6G2=6?46
1 - * %1 ! % 2?5 C:D< 724E@CD 7@C 2BF:C:78 96A2E:E:D :? 96>@5:2=JD:D
/2965: " 2CG:D9 " @89252> (0 C6BF6?4J @7 6A2E:E:D A2E:6?ED :? 2KG:?
2?5 :?764E:@?D 2>@?8 6>@A9:=:24 A2E:6?ED :? 1 51%* %1 ! %
6C>2?1 !)* %1 ! % /:26: " #2>26: " @DD6:?: (" K2C<2C (0%C6G2=6?46 @7 + :?764E:@? 2?5 C6=2E65 G:C6>:2 :?
6=2G2C: ")232E232P: (" 0 C6BF6?4J @7 6A2E:E:D 2?5 1 96>@A9:=:4 A2E:6?ED C68:DE6C65@C2D2? \$>@A9:=:2
:ED C6=2E65 724E@CD :? 3=@@5 5@?@CD :? 6C>2? :? D@4:6EJ1"+#\$! *!.\$ +* %1 ! %
+0-* (" -)4 %1 ! % .()% !,0 (% + " - *
=2G:(CK2?:2?") 2E2>: (9:C2?: 0 C6BF6?4J @7 =2G:2? (" C56D9:C: 2:2C:K2569 0%C6G2=6?46 @7
96A2E:E:D :? E92=2DD6>:4 A2E:6?ED 2?5 :ED 2DD@4:2E:@? + + 2?5 + :?764E:@?D 2>@?8 6>@A9:=:24D1
H:E9 =:G6C 6?KJ>6D >@7:5 9@DA:E2=)69C2? 1 (% !
!!- \$ %* ! % %! \$ % \$ % ! \$! \$ % \$! (2?6P: " @892552> (2G25<@@9: ('2<9D92?:
D>2P=: " " @DE272K2569 (92C32E52C2? " 0%C6G2=6?46 @7 96A2E:E:D 2?5 :? A2E:6?ED H:E9 >2;@C
2:;29>25: " =:;2?A@@C " 6A2E:E:D :? 3=@@5 6E2 E92=2DD26>:2 C676CC65 E@ =: D892C 9@DA:E2= ?
AC@5F4ED C646:G6CD ! % /- /29652? 1 (++ % - * % (++ - * .0. - #
925:C " 272C: >:C:2?: ")'6KG2? >:?: () @C23: (365 D9E:2?: 69<9@52 ' !/ (! !*!
%@FCD92>D 0 6A2E:E:D :? @=6DE2? %C@G:746 C2?1 0%C6G2=6?46 @7 6A2E:E:D 2?5 :?)92=2DD6>:4 A2E:6?ED
+1-!.\$ @7 2DE K2C32:;2? :? 1 (++ % - * % (++ - * .0. - # ! !*!
2332C: 6D92C2E (9@5232<9D9: 6A2E:E:D :? 2=29 "(2P72CD925 ' !/ (! !*!
96>@5:2=JD:D 46?E6CD @7 @=6DE2? AC@G:746 ?@CE962D?@FC 92?26: 0%C6G2=6?46 @7 96A2E:E:D 2?5 96A2E:E:D 2?5 E96:C C:D<
C2? !, / +* 724E@CD 2>@?8 F:=2? 3=@@5 5@?@CD (++ % - * % (++ - * .0. - # ! !*!
=2G:2? (" 2:2C:2K569 "2=6<K2569 ' 0 6A2E:E:D (FA
:? 6>@A9:=:24D1 +1-!.\$ "2952G:2?: (2C6>: ('27:66 " 0%C6G2=6?46 @7
=2G:2? (" 9@=2>: "2D2CC2E (6A2E:E:D C:D< "2764E:@? :? E92=2DD6>:4 2?5
724E@CD :? C2?:2? G@=F?E66C 3=@@5 5@?@CD 42D6 4@96A2E:E:D 2?5 + :?764E:@? :? E92=2DD6>:4 2?5
DEF5J ./+!*/!+(!, / + (96>@A9:=:4 A2E:6?ED @7 "2C<2K: AC@G:746 :? (+#
<32C: >2?:69 " 2C>: ")232E232P: ' % - * % (++ - * .0. - # ! !*!
6A2E:E:D G:CFD 2?E:3@5J A@D:E:G6 42D6D :? "2?D@FC 92?26: 2=29 "(2P72CD925 ' @F<2C
>F=E:EC2?D7FD65 E92=2DD6>:4 A2E:6?ED @FE\$ @7 C2? (2=2C:)2G27K2569 ' %C6G2=6?46 @7 96A2E:E:D DFC7246
! , / +* 2?E:86? 2?5 96A2E:E:D G:CFD 2?E:3@5J 2?5 E96:C C:D<
@DD6:?: D= (:89 AC6G2=6?46 @7 + + + 724E@CD 2>@?8 F:=2?PD G@=F?E66C 3=@@5 5@?@CD
:764E:@? :? 8JADJ A@AF=2E:@? C6D:5:78 :? 9292C>292= !, / +* ! !*!
2?5 2<9E:2C: AC@G:746 \$+) !)+/) @C23: (365 D9E:2?: 69<9@52 ' !/ (! !*!
>:?: 27: 325 ()2=63:2? '2?:32C 6C>2?: 0%C6G2=6?46 @7 96A2E:E:D 2?5 + :? 96>@A9:=:24
"@89E252P: " (@392?: " (2>:P: (0?:? A@@= D4C66?:78 0%C6G2=6?46 @7 2DE K2C32:;2? :? 1 (++ % - * %
7@C + :?764E:@? :? C2?:2? 3=@@5 5@?@CD %C6=::?2CJA2E:6?ED @7 2DE K2C32:;2? :? 1 (++ % - * %
C6DF=ED(++ % - * % (++ - * .0. - # ! !*!
!*/ 2D2?A@FC (C2DE69 9@C32?: ("2952G: (0%C6G2=6?46 @7 6A2E:E:D 6A2E:E:D 2?5 + :?764E:@?
=2G:2? (" #6EH@C<:78 7@C \$G6C4@>:78 @? +:C2= :? J62C 2?5 @=56C A2E:6?ED 25>:EE65 :? 92?5 DFC86CJ
6A2E:E:D #6EH@C<Q/ +* +2952?: % @DD6:?: " @892552> (" " 249<2C !
(23@C @C@>2?5 % "69C23: . 92?32C: " (92C2?: %C6G2=6?46 @7 96A2E:E:D 96A2E:E:D 9F>2?
/2CC:??2> 0%C6G2=6?46 2?5 C:D< 724E@CD @7 96A2E:E:D :>F?@567:4:6?4J G:CFD 2?5 DJA9:=:D 2>@?8 DEC66E
:764E:@? :? 96>@5:2=JD:D A2E:6?ED 6C>2?D929 49:=5C6? C6D:5:78 :? D@FE96C?)69C2? C2\$ - *
1 ! \$ ++ !-) * \$ \$ %1 ! % !
92? : " +2<:=: "" %C6G2=6?46 2?5 C:D< 724E@CD @7 + 2 C2?@FD9" 9@C32?:' >: :5@<9E: " +@D@@89 %
96A2E:E:D G:CFD 2?5 96A2E:E:D G:CFD :?764E:@?D :? 5CF8 "2=6< " .2K5:92 "(0%C6G2=6?46 @7 6A2E:E:D C6DF=E65
255:4ED 2>@?8 /??:2? AC:D@?6CD \$ - * ! 7C@> 3=@@5 EC2?D7FD:@? :? >2;@C)92=2DD6>:2 A2E:6?ED :?
"@E=289 " "2<G2?5: " 2=2=: ") 0%C6G2=6?46 @7 2?E: (%>?2? 2>892? 2?5 2C>D2C 1 (+)+5#*
+ 2>@?8 AC68?2?E H@>6?1 51%* %1 ! % *%1 ! % 2:;2 (929C@<9: # >:CK2C82C !/ (%C6G2=6?46 @7
'@H92?: '2932C)232E2366 .2K5: %2?29: " 96A2E:E:D G:CFD 2>@?8 96A2E:E:D 2>@?8 2 AC:G2E6
%C6G2=6?46 @7 4@>>@? 3=@@5 3@C?6 :?764E:@?D 2>@?8 (2>:;>: '25 (92932K #@C@@K: " "29>@5: " =23@C2E@CJ :?)69C2?- * % * 0 (!/(\$
>:AC:D@?65 :?64E:@C\$5 FD6CD :? "2D9925 #@CE9 2DE (2>:;>: '25 (92932K #@C@@K: " "29>@5: " 2JJ2K +2D689: " 0%C6G2=6?46 @7 96A2E:E:D G:CFD
@7 C2?- \$ - * ! % @ @C29>25 " 2G25J 2C>: E2P: 2DD2P:2? # 2?E:3@5J 2?5 C6=2E65 C:D< 724E@CD 2>@?8 96>@5:2=JD:D
% @ @C29>25 " 2G25J 2C>: E2P: 2DD2P:2? # HAZE:6?ED :? "2C<2K: AC@G:746 1 \$ 1 - *!.\$
(6C@AC6G2=6?46 @7 2?5 C:D< 724E@CD 2DD@4:2E65 96A2E:E:D 96A2E:E:D 2?5 9F>2? :>F?@567:4:6?4J - ' %1 ! %
96A2E:E:D 96A2E:E:D 2?5 9F>2? :>F?@567:4:6?4J G:CFD 2>@?8 AC:D@?6CD :? C2?/ % . (%* - / "@F=2 2:;2?: %C6G2=6?46 @7 96A2E:E:D G:CFD
G:CFD 2>@?8 AC:D@?6CD :? C2?/ % . (%* - / :?764E:@? :? A2E:6?ED H:E9 DJDE6>:4 =FAFD 6CJE96>2E@DFD
" @9E2D92> >:C: / '6KG2?: " 2P72C: (92<:3 ' 2P72C: '6K2K2569 " ??: 2D92?: " @92>>25: !/ ((92<:3 0%C6G2=6?46 @7 + 2?5 9:89 C:D< 3692G:@CD :?)

%C6G2=6746 @7 9F>2? :>F?@567:4:6?4J 96A2E:E:D 275 2525: 792>:(2C32<9D9 " !/ (0 A:56>:@=@8:42= 96A2E:E:D G:CFD6D :? E96 7:CDE E:>6 C6A62E 2?5 C68F=2C56E6C>:??ED @7 @44FA2E:@?2= 6IA@DFC6 E@ + + 2?5 5@?@CD :? 3=@@5 EC2?D7FD:@? 46?E6C 2>252? + :? 962=E9 42C6 H@C<6CD1!\$- *%1 !

- * *! / % . - , !

2DC2:2? !)@C23;29C@>: (0% C6G2=6746 @7 >2;@C 2C:C: "" <32C: # .2G2C: " 2G25: 2G6C (EC2?D7FD:@? EC2?D>:EE65 G:C2= :?764E:@?D + + + 0% C6G2=6746 @7 6A2E:E:D 275 + >2C<6CD :? :? (9:C2K 3=@@5 5@?@CD 7C@> E@ (+# %)92=2DD6>:4 2?5 6>@A9:=:4 A2E:6?ED :? D7292? 1 - *% * (+ + - *.0. -# ! !/ (+ + % - *% * (+ + - *.0. -# ! !/

2>2782C E2A@FC " (2?6: "@89252> /@9@FC ' #2J63 8926: (" 0% C6G2=6746 @7 D6C@=@8:4 >2C<6CD @7 2G25: % @C29>25 " E2P: 0)96 C6=2E:@?D9:A 6A2E:E:D 275 275 C:D< 724E@CD 2>@?8 56?E:DED 2?5 36EH66? 7C6BF6?4J 2?5 5FC2E:@? @7 :>AC:D@?>6?E 2?5 E96 AC6G2=6746 @7 D 8 ?E: + 2?5 + 2?E:3@5J D6C@A@D:E:G:EJ :? C2?:2? AC:D@?6CD1+0*%(A9JD:4:2?D :? 6C>2? C2?1 !-)* *%1 ! %

:?@==29: 2;2C:K2569 2<9E:2C: (!/ (%C6EC2?DA=2?E 96A2E:E:D G:CFD :?764E:@? 2?5 :ED 67764E@?@FCD92>D "2=6<K2569 ' <32C: "" "6CP2E (E96 A@DE EC2?DA=2?E 4@FCD6 @?C6?2=?2==@8C27E %C6G2=6746 2?5 42FD6D @7 6=6G2E65 !)=6G6=D 2>@?8 G4:A:6?ED /-+!*!-+ (!, /+ C2?:2? 962=E9J 3=@@5 5@?@CD+!*!-+ (+ #4 @K@C89: ('2>6K2?: +29:5) !/ (0)96 AC6G2=6746 2?5 2?D< 724E@CD @7 96A2E:E:D G:CFD :?764E:@? 2>@?8 2625K2569 (929D9292?: EE2C " .2G2C: ") E92=2DD6>:4 A2E:6?ED @7 &2KG:?? 1 51%* *%1 (2G23:69 (9 0(EF5J @7 E96 AC6G2=6746 @7 6A2E:E:D ! % ! % 275 + :?764E:@? :? 6>@A9:=:2 2?5)92=2DD6>:2 A@AF=2E:@? @7 .2K5 :? 1(+ + % - *% * (+ + - *.0. -# ! !/

"@92>>25 =:K2569 '2?:32C" (6J7@=6D=2>: (')96 7C6BF6?4J @7 96A2E:E:D :? 5:2=JD6 A2E:6?ED :? 2>252? <32E2? 9@DA:E2= - * *! / % . - , ! (92>D:2? CK2?:2? ") (92>D9:C: ' =2G: (9@;2DE69 \$ 0=@@5 EC2?D7FD:@? DE2EFD :? 36E2 >2;@C E92=2DD6>:2 A2E:6?ED :? "@7:9=5C6? @DA:E2= :?) 69C2?1 (+ + % - *% * (+ + - *.0. -# ! !/

=2G:2? (" 2E2>: (0 E:@=@8J 2?5 'D< 724E@CD @7 4FE6 +:C2= 6A2E:E:D :? 5F=E %2E:6?ED C6776C65 E@)69C2?) 69C2?1 (+ + % - *% * (+ + - *.0. -# ! !/ !/ 2?5 6A2E:E:D 6?E6C 7C@> 1 +1-!.\$

(2=69: (92C:7: " #@C@@K #6;25 " +2K:C:2? (9 0(6C@6A:56>:@=@8J @7 + + + :?764E:@?D :? =23@C2E@CJ DE277 6C>2?D929 1!\$++ !-)*\$ \$ *%1 ! %

" @?:C: ' "@D2JJ63: / "@D2G: (6C@AC6G2=6746 @7 4JE@>682=@G:CFD 96A2E:E:D 96A2E:E:D 275 9F>2? :>F?@567:4:6?4J G:CFD 2?E:3@5:6D 2>@?8 G@=F?E66C 3=@@5 5@?@CB*%* 0 (!/\$

#2DD:C:)@D:" !2CE: '2DE69 " !/ ('D< 724E@CD 2?5 D6C@AC6G2=6746 @7 96A2E:E:D 275 :?764E:@?D 2>@?8-*,(96>@5:2=JD:D A2E:6?ED :?)69C2?- * /\$+)2C6>: " 9@D932E6? " 249<2C! 9D2?: C52<2?: " /2=: " 6A2E:E:D G:CFD :?764E:@? :? 96>@5:2=JD:D A2E:6?ED 2 D6C@6A:56>:@=@8:42= DFCG6J :?*C2? %.

)2>255@?: "@92>>25K2569 /:2P: \$ (6C@AC6G2=6746 @7 + 2?E:3@5J 2>@?8 A2E:6?ED H:E9 36E2 E92=2DD6>:2 >2;@C :? >:C<@=2)92=2DD6>:2 6?E6C C2?- * ((!#A ./\$)))0*+()2C6>: " 249<2C! "29>@F5 C23: (96C25A6K9@F9 " 9@D932E6? " %C6G2=6746 @7 2?E:3@5:6D E@ 96A2E:E:D G:CFD 2>@?8 >2=6 3=@@5 5@?@CD :?)23C:K D=2>:4 '6AF3=4 @7 C2? / !%!-- !/\$

(2772C " @@J2? ' "2952G: "" 92=:=:2? ' (6C@AC6G2=6746 @7 96A2E:E:D 275 275 96A2E:E:D G244:??E:@? DE2EFD 2>@?8 962=E9 42C6 H@C<6CD :? (2C)2?@>2?5 "@?E2K2> 27D9?@49: " C2? 5* - *% ! % (6C@6A:56>:@=@8J @7 96A2E:E:D 2?E:3@5J 36EH66? CFC2= 2?5 FC3? A6@A=6 C6EC@DA64E:G6 DEF5J :? F?6 E@ 646>36C @7 :? "2=6<2? :EJ C2? !. %+(%

927@@C:2? C@F;6C5?:2" DD2C69K25682? " /2?5:2? 9 (6C@AC6G2=6746 @7 6A2E:E:D 6A2E:E:D 2?5 9F>2? :>F?@567:4:6?4J G:CFD + 2>@?8)92=2DD6>:2 A2E:6?ED C676C E@ 9H2K (92A92 @DA:E2= %!?!% "% !% (+0-* ()2=2:6 (925?:2 (\$<2K: %2;@F9>2?5 2D2?:2? C:2?A@C@C)96 AC6G2=6746 @7 96A2E:E:D 96A2E:E:D 275 + :?764E:@?D :? ?@? + 5CF8 @A:@:5 A@:D@?65 A2E:6?ED :?)69C2? C2? %./ * %+(%

2C:>: " 92G2?:? (6C@AC6G2=6746 @7 96A2E:E:D 96A2E:E:D 2?5 9F>2? :>F?@567:4:6?4J G:CFD 2?E:3@5:6D 2>@?8 >F=E:EC2?D7FD65 E92=2DD6>:4 49:=5C69:C2K C2? +0-* (+ " !% /-% . * \$(!/\$

"@9E2D92> >:C: / 2P72C: (92<:3)@@C49: '@@5D2C: " (6C@AC6G2=6746 @7 96A2E:E:D 275 C:D< 724E@CD :?764E:@? 2>@?8 2?5 96>@5:2=JD:D A2E:6?ED :? F=:2? AC@G:746 C2? \$

69?2K " 69?2K "@92>>25K2569 " 0)96 AC6G2=6746 @7 96A2E:E:D :?764E:@? 2>@?8 E96 56?E:DED @?C:7: "@@5 "6E2?2E " @ :?764E:@? + D 2?5 .2K5 2?5 2DD6DD>6?E @7 E96:C <?@H=6586 2625K2569 D1 !*/

(@>: " 6:G2?: C52=2? "" 2C9278 (%@FC: 6A2E:E:D G:CFD 6?@EJA6D :? A2E:6?ED H:E9 ?5 (E286 '6?2= :D62D6 :? 2DE K2C32;:2? C2? 0 % %!4 % . -*,(92C:7: "@@5 (2?6: "@892552> ((2=69: " D989: % 9@DC2G: (92=:=: " +:C2= :?764E:@? 2>@?8 A2E:6?ED H:E9 96>@A9:=:2 :? E96 (@FE962DE @7 C2?! %

(92C:7: "@@5 "6E2?2E " @ :?764E:@? + D 2?5 6A2E:E:D *!-* %-(92C:7: "@@5 "6E2?2E " ?764E:@? 2>@?8 9@DA:E2=:K65

```

:?:64E:@? 5CF8 FD6CD %
(92C:7: "@@5 9@DC2G: ( )2EE@@:78 >2:@C D@FC46 7@C'2932C ' '@@9@=>?:? ( 9@D9?@@5 %C6G2=6?46 @7
G:C2=:?:764E:@? ! %
+ :?764E:@? 2?5 @E96C 3=@@5 3@C?6 :?764E:@?D :?
(92C:7: "@@5 D989: % (2?6: "@892552> 2D96>:
:742C46C2E65 2?5 ?@?:?42C46C2E65 :?:64E:@? 5CF8 FD6CD
" 6A2E:E:D 2?5 G:CFD :?764E:@?D :? A2E:6?ED H:E9
*D :? "2D9925 C2? /* -0# +(
96>@A9:=:2 :? /29652? D@FE962DE C2? % !

(92C:2EK2569 (" #2556C: 9 0(EF5J @7 + +
2?5 + :?764E:@? :? > 2;@C )92=2DD6>:4 A2E:6?ED :?
6?EC2= AC@G?:46 @7 C2?+)% *%1 ! %
% @FC92>D "2=6<K2569 ' "@?2GG2C: !/ (
%C6G2=6?46 2?5 6E:@=@8J @7 A6CD:DE6?E=J 6=6G2E65 2=???:?6
2>:>@EC2?D76C2D6 =6G6=D :? 962=E9J C2?:2? 3=@@5 5@?:@CD
./-+!*/!+ ( !, /+ (
% @C>2?5 ' % @C>2?5 " (2=6> ( !/ ( 0% @DE
EC2?DA=2?E2E:@?:?764E:@FD 4@>A=:42E:@?D :? C2?:2? <:5?6J
C64:A:6?ED AC@DA64E:G6 DEF5J @7 A2E:6?ED
0 ( % !/($ !/($ !. */
% @FC2K2C 3<32C: # 2C:C: " .2G2C: <32C: (9
0 G2=F2E:@? @7 56>@8C2A9:4 AC@75=6G2=6?46 @7
>2;@C G:C2= >2C<6CD :? 7:CDE E:>6 GD C6A62E 3=@@5 5@?:@CD :?
D7292?1 ( ++ % - * * ( ++ - * .0. -# !.
!*/
"29>@@5:2? (9@ @D9E2C: " % @C72E9@==29 ?
@G6CG:6H 2?2=JD:D @7 3=@@5 5@?2E:@? :? E96 D=2>:4
'6AF3=:4 @7 C2?- $ - * !
#@FC @:;@CJ (=2@55@H=6:6 (655:89:2? 077:424J @7
4@ :?764E:@? :? C2? D6C@6A:56>:@=@8:42= 32D65 DEF5J4@?:?56?E:2= D6=7 6I4=FD:@? 2?5 72D65@D @? 3=@@5
% / * % + ( %
5@?2E:@? D276EJ :? (2C: 2?5 69D929C 3=@@5 5@?:@CD1
( ++ % - * * ( ++ - * .0. -# !. !*/
(2J25 (92>D655:?(2665 6JG2?: !/ (
(6C@6A:56>:@=@8J @7 96A2E:E:D :? 6C>2?D929 ,6DE @7
C2? !, / + *
#@FC @:;@K: 6A2E:E:D
??:3@5J 2?5 C6=2E65 C:D< 724E@CD :? 96>@5:2=JD:D A2E:6?ED
: ? C2? ) + !,$+ ( + #4
"6C2<9D92? @C72C
5@?:@CD :? /29652? =@@5 )C2?D7FD:@? 6?E6C 0 ? %6CD:2?1 6C2<9D92? "2<2C:2? '2;23 ?2=JD:D @7 E96 C6=2E65
724E@CD 96A2E:E:D G:CFD :?764E:@? 2>@?8 96>@A9:=:4
A2E:6?ED :? D7292? C2?, / + *
(2?2P:K2569 )289255@D:76;25 >@P: " 2J2E>2<@@@
"@C25: " @9289689: (929C2<: ( !/ (
29:> % FE@AD:6D @? 3@5:6D H:E9@FE 2?E6>@CE6> C:D<
(6C@6A:56>:@=@8J @7 CF36==2 >62D=6D + + 2?5
724E@CD 7@C + + 2?5 + :?764E:@?D C6 E96J D276
G:CFD H:E9?: H@>6? :? 49=:5 362C:78 286D (2C2G2?:EJ @7
/$+ ( + #4
(:DE2? 2?5 =@@492DE2? %C@G?:46 % - + % + (
(2?2P:K2569 (6C@AC6G2=6?46 @7 + + 2?5 + :?
7@C6?D:4 2FE@AD:6D H9:49 92G6 366? AC6DF>65 E@ 36 =@C?2D6C: (" % @DE49: #2DD6C: "@892552> ( !/ (
C:D< :? )69C2? E96 2A:E2= @7 C2?!-!*/ /$+ (
0 + :? :?EC2G6?@FD 5CF8 FD6CD1+1-!.$

(2=69: " (92C:7: 4FE6 G:C2= 96A2E:E:D :? /29652?
":C>@>6? ( =2G:2? (" 2;2C:K2569 !/ (
D6C@=@8:42=2?2=JK6D @7 42D%
A:56>:@=@8J @7 96A2E:E:D 96A2E:E:D 2?5 9F>2?
(2=69: " (2?6P: "@892552> @K@C8K2569 ('
:>F?@567:4:6?4J G:CFD :?764E:@?D :? A2E:6?ED H:E9 36E2
289:89: " 0(6C@6A:56>:@=@8J @7 96A2E:E:D :? (:DE2?
E92=2DD6>:2 :? C2? 2>F=E:46?E6C DEF5J - * !
2?5 2=@@496DE2? AC@G?:46! $ - # $ !.

":C29>25:K2569 ' 25:G2C " 6>>2E: ' 2G25:
?764E:@? H:E9 + 2?5 96A2E:E:D 2?5 G:CFD6D
(2=69: " (2?6: " 9@DC2G: ( 0 E:@=@8J @7 24FE6 G:C2=
"2D26=: / 236C: " ' "28D@F5=@F " 0 4@>A2C:D@? @7
6A2E:E:D :? /29652?1 !!- $ % * ! % % * ! $ $ %
D6C@AC6G2=6?46 @7 3=@@5 3@C?6 :?764E:@?D 2>@?8 C68F=2
!$!.$% $ !
DA@C25:4 2?5 7:CDE E:>6 3=@@5 5@?:@CD :? (D7292?1
(2568: 2K2C82?: CD9: ( " @CE2K2K2569 !/ (
- * * ( ++ - * .0. -# !. !*/
0 62=E9 DE2EFD 2>@?8 >:8C2?E EC:36D D92J6C @7 C 523:= "2C52?: @DD6?: ( 96:C<929: # 0(EF5J @7
AC@G?:461- % ( *%1 ! %
4@?:?56?E:2= D6=7 6I4=FD2@D4?: &@> '68:@?2= =@@5
(25689: 0%C6G2=6?46 @7 6A2E:E:D 2?5 :? 3=@@5
)C2?D7FD:@? 6?E6C( ++ % - * * ( ++ - * .0.
5@?:@CD 2DE K2C32:;2? AC@G?:461-+)% *%1 !
-# !. !*/
%
"2?D@FC 92?26: @C@E2? 2==29 "( !/ (
(232J2? "@PE2>65:72C " /2>:C: # 2C2>:72C
0 6A2E:E:D G:CFD6D D6C@>2C<6CD 2?5 =:G6C 7F?4E:@? :?
9@965CJ +:C2=:764E:@?D AC6G2=6?46 2?5 4@DED
F:=2? 96>@A9:=:21 0%( * %%1 ! %
J62C 9@DA:E2= 32D65 C6EC@DA64E:G6 @3D6CG2E:@?2= DEF5J :?
(9:C2K C2? ' ! %
"2<9=@@89 "2952G: " 289D96?2D " 92D6>:2?
'6KG2? "@@D2G: 2965 / %C6G2=6?46 6E:@=@8J @7 24FE6 ' 2>D9:5: " 6A2E:E:D AC6G2=6?46 :? 96>@5:2=JD:D
G:C2= 96A2E:E:D :? 9@DA:E2=:K65 A2E:6?E 2E :?764E:@FD H2C5A@7:6?ED :? '2K2?52C2? C2? DFCG6J 3A @=J>6C2D6
> 2;@C E6249:78 9@DA:E2=D )69C2? !*/ % . +,
492: ? C624E:@? 2?5 D6C@=@8:42= >6E9@52+ ( %

```

"2952G:2?: (2C6>: ("289D@5=@@ " %@@C72E9@==29 2:;2?: "2D;65:K2569' 2D96>: K>: " 2;23:)
0%G6G2=6746 @7 3=@@5 EC2?D>:EE65 G:C2= :?764E:@?D 6A2E:D G:CFD EC2?D>:DD:@? 2?5 :ED C:D< 724E@CD H:E9?:
C68F=2C 2?5 ?@? #2C4@E:4 255:4E65 %6CD@?D '676CC6896@EE
(++ % -*%* (++ -*."0. # !. !*/ D@FE96C? C2? 9FK6DE2? +-(./-+!*/!-+)
(FA
9@52525:K2569 D>26:=: #25>: @DD6?: (9256C: "2<9>2=327 /)96 C6=2E:@?D9:A 36EH66?
(9232?: (929C3232<: / 0)96 %C6G2=6746 @7 + + =:496? A=2?FD 2?5 96A2E:E:D :? :C;2?5 C2?%*- 5
2?5 +: ? #2C4@E:4 255:4E65 %6CD@?D '676CC6896@EE !% (+0-* ()
%2E:6?E =:?:4 @7 '27D2?:2? *:G6CD:EJ @7 "65:42=(4:6?46D 2?;: (272G: " #@FC2P: " !/ (0:86DE:G6 2?5 =:G6C
: ? 1 ".*&* %1 ! % 5:D62D6D DE2E:DE:4D :? D6G6C2= C676CC2= 46?E6CD :?)69C2?
96C25A6K9@F9 ")2C6>: " 249<2C! 8923@K@C8: (1 +1-!.\$
9@D932E6? " %C6D6746 2?5 D:8?:7:42?46 @7 EC2?D7FD:@? 2CK2?69 ('6K2 (" @=64F=2C 492C24E6C:DE:4
EC2?D>:EE65 G:CFD :?764E:@? ? C2?:2? A2E:6?ED @? 2?5 6A:56>:@=@8J @7 96A2E:E:D G:CFD6D :? E96 (9:C2K
>2?:E6?2?46 96>@5:2=JD:D % + %+()0*+(**)!/ %C@G:746 @7 C2?%* %+(()
D>2P:=: " " @DE272K2569 (92C32E52C2? " 2:;29>25: " =:;2?A@@C " 6A2E:E:D :? 3=@@5
965>2E 2==29:2? 3@=892D6>: !/ (AC@5F4ED C646:G6CD 5F6 E@ 24FE6 :==?6DD 367@C6 D4C66?:?8
(6C@6A:56>:@=@8:4 (EF5J @7 6A2E:E:D +:CFD 6A2E:E:D AC@8C2>! % /- !.
+:CFD F>2? >>F?@567:4:6?4J +:CFD 2?5 (JA9:=:D D>2P:=: 2>:5J2 / " :C=2E:7: (!/ ((6C@AC6G2=6746
?764E:@?D :? C2?:2? @=@5 @?@CD %+ % @7 3=@@5 3@C?6 :?764E:@?D 2>@?8 3=@@5 5@?@CD :? @FD969C
9256? >D2C: " \$>C2?: " G2=F2E:@? @7 5:28?@DE:4 C2? /*/%)% + # ()
G2=F6 @7 !(>E9@5 %' :? 5:28?@D:D * "2?D@FC 92?26: 2==29 "((927289: !/ ()
96A2E:E:D G:CFD :? 96>@5:2=JD:D A2E:6?ED +* %C6G2=6746 @7 96A2E:E:D 2?5 D6C@>2C<6CD 2?5
2DC2:2? !)@C23 29C@>: 2C292?8:K DFCG6J @ 7 6A:56>:@=@8:42= DE2EFD @7 96A2E:E:D :?764E:@? 2>@?8 23?@C>2= =:G6C 7F?4E:@? E6DED 2>@?8 96>@A9:=:24D :?
(9:C2K:2? 3=@@5 5@?@CD :? (%* %+() F:=2? ?@CE96C? AC@G:746 @7 C2? % +*%/
() @92? # /?569) (2>:6: (E2:6 / 2G2C: ")96
2DC2:2? !)@C23 29C@>: 2C292?8:K)C6?5D :? AC6G2=6746 2?5 4=:?:42= D:8?:7:42?46 @7 96A2E:E:D 2?5
:74:56?46 @7 >2:@C EC2?D7FD:@? EC2?D>:DD:3=6 G:C2@F>2?5 35@==29 (92>D9:C2DK ' 2>82C " !/ (4@:7?64E: @? ! %
:764E:@? :? 2CD 3=@@5 5@?@CD 7C@> E:= 6?5 @7 %C6G2=6746 @7 96A2E:E:D :?764E:@? 2?5 :ED C:D< 724E@CD :?
+3 #0%*% . 96>@5:2=JD:D A2E:6?ED :?)69C2? %C6=:>:2A@CCE 7C@> NE96 67764E @7 5:2=JD:D F?E :D@=2E:@? @? E96 :?4:56?46 @7
2D967 (2C>: " >:C89@7C2? / !/ () 96A2E:E:D :? 5:2=JD:D A2E:6?ED AC@G:746 % *14
?E:A9@DA9@=:A:5 2?E:3@5:6D 2?5 96A2E:E:D G:CFD 96A2E:E:D :? 5:2=JD:D A2E:6?ED AC@G:746 % *14
:764E:@? :? C2?:2? E92=2DD6>:2 >2:@C A2E:6?ED % . -*,.(
!)/+ C@F>2?5 2>82C " 6<96:C?2 " !/ (?4:56?46 @7
2C>: (6C@AC6G2=6746 @7 + + 2?5 + 2>@?8 96A2E:E:D G:CFD :?764E:@? 2?5 :ED C:D< 724E@CD 2>@?8
:7EC2G6?@FD 5CF8 FD6CD :? C2? (%* %+() 96>@5:2=JD:D A2E:6?ED :?)69C2? >F=E:46?E6C DEF5J
() + !,\$+-()
25:G2C " " :C29>25:K2569 " 2C>: 6>>2E: @K@C89: (9>25K25 D= " '2>6K2?: 2C82C72C5
)96 AC6G2=6746 @7 96A2E:E:D 2?5 F>2? =2G:2? (" 0(EF5J @7 +:C2= :?764E:@?D %C6G2=6746 :?
>>F?@567:4:6?4J +:CFD 2?E:3@5:6D :? E92=2DD6>:4 =@@5 @?@CD @7 &2KG:? %C@G:746 :? :776C6?E)>6
A2E:6?ED :? (9:C2K! - * +, L ?E6CG2=D 2?5 FC:78 2> 2CE9BF2<61 +1-!.\$
2G25: G;82? " 27:K: " %C6G2=6746 @7 + 2?5
+ :?764E:@?D 2?5 2DD@4:2E65 C:D< 724E@CD :? 255:4E9@5232<9D9: 332D: 252P: '23:P: "
AC:D@?6CD*%* 0 (!/(\$ %C6G2=6746 2?5 C:D< 724E@CD @7 + 96A2E:E:D G:CFD 2?5
29278:C?6;25 " 2<G2?5: " 6=:D925: " :K25:<92+ 96A2E:E:D G:CFD :?764E:@?D :? 5CF8 255:4ED 2>@?8 @C82?
(EF5J @? 96A2E:E:D G:CFD :?764E:@? 2>@?8 E96 56?E2= AC:D@?6CD %
DEF56?ED%+ \$!) !(- \$ EE2C49: / 927@FC: " 2:;36:8: DD2C: (9 0=2G:2?
252=: / D=2>: " (2?P2E: " !/ (6A2E:E:D G:CFD 5" @?@C 5676CC2= 2?5 3=@@5 3@C?6 :?764E:@?D :? 3=@@5
2?E:3@5:6D 2?5 +:E:=:8@ 5:D62D6%* 0 (!/(\$) @?@CD @7)69C2?+ % - *%* (++ - *."0.
-# !. !*/
"@9E2D92> >:C: / %C6G2=6746 @7 96A2E:E:D G:CFD DD2C69K25682? " (92<6C:76;25 >:?: '6K266
:764E:@? 2?5 C:D< 724E@CD :? 2? :?42C46C2E65 A@AF=2E:@?:(6C@AC6G2=6746 @7 96A2E:E:D G:CFD :? 3=@@5 5@?@CD :?
C2? \$+) !)/+ 9FK6DE2? %C@G:746 (@FE9H6DE C2? **)!/ %.
>2?:' 2C>: 2D26?2? # 0)96 C6=6G2?46 @7 C6=2E65
C:D< 3692G:@CD 2?5 D6C@AC6G2=6746 @7 + + 2?5 + D25: ("2C:2?: " 0A:56>:@=@8J 2?5 A C6G2=6746 @7
:764E:@? :? :?EC2G6?@FD 5CF8 FD6CD 7C@> (929C6<@C5?764E:@FD 5:D62D6D :? + :? :?764E:@FD ,2C5D @7 (929:5
C2? 1 \$!+!- *%1 ! % 696D9E: *:G6CD:EJ @7 "65:42=(4:6?46D 1 - *
@DD6?: "@892552> (" 6JG2?: 2D:C: !/ (**)!/ % . +, !
:DEC:3FE:@? @7 96A2E:E:D G:CFD 86?@EJA6D 2>@?8D2C:)232E232: (0(EF5J @7 724E@CD :? >2:@C 36E2
96>@5:2=JD:D A2E:6?ED :?)69C2?M2 >F=E:46?E6C DEF5J E92=2DD6>:2 4@>A=:42E:@?D :? A2E:6?ED 25>:EE65 E@ (929:5
! %+(2DE892:3 9@DA:E2= :? (9:C2K C2? 1 511 -
2:;2?: 2D96>: "2D;65:K2569 ' (92J6DE69 ! %
52?: '2;23: (6C@6A:56>:@=@8J @7 96A2E:E:D 2?5 :ED ?D2C: 2>2?: C323: (2C:@ %C6G2=6746 @7
C:D< 724E@CD :? 9FK6DE2? %C@G:746 D@FE9 H6DE @7 C2?96A2E:E:D 2?5 C6=2E65 724E@CD 2>@?8 36E2 E92=2DD6>:2
42D6 4@?EC@= DEF5J+-(./-+!*/!-+>2;@C A2E:6?ED :? (@FE96C? C2? :? ! %

892:2?:A@@C /2?5:69) 0(6C@6A:56>:@=@8:42= @55 '. #@E2C: %E (EC2>6C (! FCC6?E AC6G2=6?46
?:G6DE:82E:@? @7 6A2E:E:D 2?5 + G:CFD :? D276 3=@@5 2?5 :?4:56?46 @7 :?764E:@FD 5:D62D6 >2C<6CD 2?5 6DE:>2E65
5@?@CD @7 23@= =@@5)C2?D7FD:@? (6?E6C% H:75@H A6C:@5 C:D< :? E96 >6C:42? '65 C@DD 3=@@5 5@?@C
- *% * (++ - *."0. -# !. !*/ A@AF=2E:@? ".0.%+*
7K2=:)2892G: C52<2?: +2=: ' 9:2G6EE2 D4@32C " #6H>2? !/ (?4:56?46 2?5
0(6C@6A:56>:@=@8J @7 6A2E:E:D 2?5 :? 3=@@5 5@?@CD :6DE:>2E65 C2E6D @7 C6D:5F2= C:D< 7@C + 96A2E:E:D
2D92? 1 145 . \$ * %1 ! % 96A2E:E:D 2?5 9F>2?) 46== =J>A9@EC@A:4 G:CFD6D :?
3=@@5 5@?@CD :? 2?252 * ! ..+

K2C<2C / (92C:7K2569 " :C2<: " 0%C6G2=6?46 @7
6A2E:E:D 2?5 2?5 + :? AC:D@??65 A6@A=6 :?
:C:2?51 %-&* *%1 ! % \$776C86=5 ' 26?D6? 'EE6C (2>@F52 \$ F>2?
=:2G:2? (" 2;2C:2K569 @C@@5:) !/ (0(EF5J @7 :>F?@567:4:6?4J G:CFD 96A2E:E:D 2?5 96A2E:E:D
96A2E:E:D 2?5 AC6G2=6?46 :? E92=2DD6>:4 >2;@C :?764E:@?D 2>@?8 3=@@5 5@?@CD :? 6C>2?J :D
A2E:6?ED @7 &2KG: ? AC@G:7462 - ! @7 G:CFD EC2?D>:DD:@? 2?5 E96 :>A24E @7 ?F4=6:4 24:5
2>A=7:42E:@? E6DE:78+ 0-1!%(
+6=2E: @>:2EE: ! 2CF77: ! '>2?@ ! /2?6EE:
>66? ' (2?25 # = (96>>2C: (!/ (%C6G2=6?46 @7 >A24E @7 ?F4=6:4 24:5 2>A=7:42E:@? E649?@=@8J #) :?
G:C2= >2C<6CD 2>@?8 7:CDE E:>6 C23 3=@@5 5@?@CD :E2=J :? E96 E9C66 J62CD 7@==@H:78 :>A=6>6?E2E:@?
FH2:E - *."0.%+* 0+ 0-1!%(
2H " =<236C " C29 " ,6C72==: "" :92E @?K2=6K " '68:76 + %:44:?:? + +F=42?@ :2>A2@=@
(:2=2 " %C6G2=6?46 @7 96A2E:E:D G:CFD 2?E:3@5:6D 2>@?8 2DD2? ' 6D:5F2= C:D< @7 EC2?D7FD:@? EC2?D>:EE65
5:776C6?E A@AF=2E:@?D @7 C6=2E:G6 2?5 2EEC:3FE23=6 9F>2? :>F?@567:4:6?4J G:CFD 96A2E:E:D G:CFD 2?5
0 % ! 96A2E:E:D G:CFD :?764E:@?D :? E2=1".0.%+*

=(@?29F6 "" &FC6D9: +6C>F?5 (6A2E:E:D
2?5 96A2E:E:D :? %2<:DE2? AC6G2=6?46 2?5 C:D< 724E@CD%C2E:)C2?D>:DD:@? @7 96A2E:E:D G:CFD 3J 3=@@5
*/ !/ % . EC2?D7FD:@?D 2?5 @E96C >65:42= AC@465FC6D 2 8=@32=
(2?56D9 +2C896D6) 2C:<F>2C ' !/ (%C6G2=6?46 @7 C6G:6H !, /+(
6A2E:E:D 2?5 :? E96 ?@C>2= A@AF=2E:@? 2?5 9:89 C:D< !:F % (9: /- /92?8 . -F / (9F (/92?8 .
8C@FAD :? ?@CE9 6C2+2 ./+!*!/+ AC@DA64E:G6 DEF5J @7 2 D6CF> A@=@=:?8?D6C66378
3=@@5 5@?@CD 7@C 2?E:3@5J E@ 96A2E:E:D G:CFD
- *."0.%+*

C56? (FJF<@KEFC< (2=2?8F (.:=>2K %2=2?5FK
(25FC (DEF5J @7 D6C@=@8:42= >2C<6CD @7 96A2E:E:D "F,663 (27:K !@H 4@DE D4C66?:?8 @7 3=@@5 7@C +
2?5 G:CFD6D :? DE2?3F=)FC<6J! -%* - / :?764E:@? :? E96 56G6=@A:78 H@G=5 *#

!69>2? " ,:=D@? " ! A:56>:@=@8J @7 96A2E:E:D)92<C2= "2CH292 # 92H=2. !/ (%C6G2=6?46
G:CFD6D 2>@?8 96A2E@46==F=2C 42C4:??>2 42D6D 2?5D:8?:7:42?46 @7 96A2E:E:D G:CFD + D6C@A@D:E:G:EJ :?
962=E9J A6@A=6 :? 8JAE 2 DJDE6>2E:4 C6G:6H 2?5 >6E2 3=@@5 5@?@CD * ! !
2?2=JD:D * / * !- 2?5@EE: (2C<@5:6 ==2:? % '6D:5F2= C:D< @7
-:2 - !F@ 2: .F ' A:56>:@=@8J @7 96A2E:E:D EC2?D7FD:@? :? 92?2- !) /+(
G:CFD :?764E:@? 2>@?8 :?;64E:@? 5CF8 FD6CD :? 9:72 2>6=" 92772C . ,2D67 " ,C:89E " =2C<!
DJDE6>2E:4 C6G:6H 2?5 >6E2 2?2=JD:D (% !/(\$ " :==6C :89 + AC6G2=6?46 :? 8JAE:2? 3=@@5
5@?@CD !/

(EG:=:2)D6CEDG25K6) (92CG25K6 ! !/ (%C6G2=6?46 @7 '6KG2? 3@=892DD6>: 27:2325 ()C2?D7FD:@?
96A2E:E:D + 2?5 C:D< 3692G:@CD 7@C 3=@@5 3@C?6 EC2?D>:EE65 :?764E:@?D 2>@?8 >F=E:EC2?D7FD65 A2E:6?ED :?
:764E:@?D 2 A@AF=2E:@? 32D65 DFCG6J @7 E96 25F4E2? C6G:6H - *."0. !
A@AF=2E:@? @7)P3:=:D: '6AF3=:4 @7 6@G8:2 (:=G2 ! (:=G2 " '@52CE !/ (%C6G2=6?46 @7
!(/\$ 96A2E:E:D G:CFD + :?764E:@? 2?5 + 86?@EJA6D @7
C>DEC@?8 ! ,2D=6J (:>2C5 % "4&F==2? " 96>@5:2=JD:D A2E:6?ED :? (2=G25@C #@CE962DE6C? C2K:=
F9?6CE ,! =E6C ")96 AC6G2=6?46 @7 96A2E:E:D - 5 ! %+(!
G:CFD :?764E:@? :? E96 *?:E65 (E2E6D E9C@F89 2CC:=)C2G6C 64C62D6 :? E96 96A2E:E:D G:CFD
** */!- * ! + AC6G2=6?46 :? 96>@5:2=JD:D A2E:6?ED :? (A2:? 67764E
2=6ED<: ((6?:FE2 # (JCED6G +!/ (0?2=JD:D @7 @7 E:>6 :?:E:2E:78 + AC6G2=6?46 DEF5:6D 2?5 25@AE:@? @7
D@>6 G:C2= :?764E:@?D EC2?D>:EE65 3J A2C6?E6C2= 2?5D@=2E:@? >62DFC661% - !
D6IF2= C@FE6D :? E96 '6AF3=:4 @7 K6C32:2? %0.-+(=2G:2? (" D9:6=5 282?:DE 2 >@?DE6C 6A2E:E:D :?
96>@5:2=JD:D A2E:6?ED +-(./+!*!/+

C:E@ +\$ %2CC2 2449:?: ' F492==2 " 0 +
:764E:@? 96A2E:E:D 2?5 2?5 DJA9:=:D :? 9@>6=6DD 6?E:4@ % F@?8:@C?@ ' +@=A6 !/ (%C6G2=6?46 2?5
A6@A=6 :? E96 4:EJ @7 (2@ %2F=@ C2K:=D! :?4:56?46 @7 96A2E:E:D G:CFD + :? 96>@5:2=JD:D
0 (% A2E:6?ED DEF5J @7 C:D< 724E@CD !, \$-+(
"2E6F 6=236CE %)C6=@2C 2=2E2JF5 + !/ (@H
42? 96A2E:E:D 36 AC6G6?E65 :? E96 =@?8 E6C>-0#
+(% 4 =2G:2? (" ,6 #665 2 #6H #2E:@?2= AAC@249 E@
@?EC@= 6A2E:E:D E :D 64@>:78 E@ @ !?E6+*

=2G:2? (")232E2326: (+ ' (6CF> G:C2= >2C<6CD :?
C2??:2 A2E:6?ED H:E9 4@?86?:E2= 3=665:28C56C*
0 % !
=2G:2? (")C:2?8F=2C =:?:4D)96 ,2J @7)96 FEFC6
! , / +*